Minerva Neurosciences, Inc. financial data

Symbol
NERV on Nasdaq
Industry
Pharmaceutical Preparations
Location
1601 Trapelo Road, Suite 286, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 922 % -52.5%
Debt-to-equity -250 % +37.4%
Return On Equity 10.1 % -92.8%
Return On Assets -6.74 % +85.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.99M shares 0%
Common Stock, Shares, Outstanding 6.99M shares 0%
Entity Public Float 36.9M USD +116%
Common Stock, Value, Issued 699 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.57M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 7.57M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.6M USD +31%
General and Administrative Expense 9.86M USD +0.19%
Operating Income (Loss) -24.5M USD -16.6%
Net Income (Loss) Attributable to Parent -3.31M USD +88%
Earnings Per Share, Basic -0.4 USD/shares +91.5%
Earnings Per Share, Diluted -0.4 USD/shares +91.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.5M USD -43.4%
Assets, Current 27.9M USD -42.1%
Property, Plant and Equipment, Net 6.8K USD -44.5%
Goodwill 14.9M USD 0%
Assets 42.8M USD -32.2%
Accounts Payable, Current 553K USD -60.3%
Liabilities, Current 4.48M USD +33.8%
Liabilities 64.5M USD -22.5%
Retained Earnings (Accumulated Deficit) -391M USD -0.85%
Stockholders' Equity Attributable to Parent -21.7M USD -8.1%
Liabilities and Equity 42.8M USD -32.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.09M USD -5181%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 6.99M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.09M USD -5181%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.6M USD -43.3%
Deferred Tax Assets, Valuation Allowance 96.9M USD +7.5%
Deferred Tax Assets, Gross 96.9M USD +7.5%
Deferred Tax Assets, Operating Loss Carryforwards 34.5M USD +29.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 431 USD -51.6%
Share-based Payment Arrangement, Expense 1.69M USD -26.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%